ADAM22 acts as a novel predictive biomarker for unfavorable prognosis and facilitates metastasis via PI3K/AKT signaling pathway in nasopharyngeal carcinoma
Open Access
- 14 March 2024
- journal article
- research article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 256, 155264
Abstract
No abstract availableKeywords
Funding Information
- Guangzhou Municipal Science and Technology Project (202102021165)
- Guangzhou First People's Hospital
- National Natural Science Foundation of China (81702879)
- Guangdong Provincial Natural Science Foundation (2021A1515110094)
This publication has 65 references indexed in Scilit:
- Key radioresistance regulation models and marker genes identified by integrated transcriptome analysis in nasopharyngeal carcinomaCancer Medicine, 2021
- Pattern and prognosis of distant metastases in nasopharyngeal carcinoma: A large‐population retrospective analysisCancer Medicine, 2020
- Current Perspectives on Nasopharyngeal Carcinoma2019
- Epithelial-to-mesenchymal transition in cancer: complexity and opportunitiesFrontiers of Medicine, 2018
- Epithelial–mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesisJournal of Cellular Physiology, 2017
- ADAM22 as a Prognostic and Therapeutic Drug Target in the Treatment of Endocrine-Resistant Breast Cancer2013
- Snake venom metalloproteinases: Structure, function and relevance to the mammalian ADAM/ADAMTS family proteinsBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2012
- ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathwayMolecular and Cellular Biochemistry, 2011
- ADAM 10 is associated with gastric cancer progression and prognosis of patientsJournal of Surgical Oncology, 2010
- The ATM tumour suppressor gene is down‐regulated in EBV‐associated nasopharyngeal carcinomaThe Journal of Pathology, 2008